ArticleBritish journal of haematology2012
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
Article in British journal of haematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed.
- IAP antagonists induce anti-tumor immunity in multiple myeloma.Nature medicine · 2016Trial
- Engineering bone marrow in a dish-a bloody business: preclinical opportunities, translational use cases, and a call for consensus.Journal of thrombosis and haemostasis : JTH · 2026Review
- Diagnosis, risk stratification and management of smouldering multiple myeloma.Nature reviews. Clinical oncology · 2026Review
- Convergent Multistage Evidence Implicates the CCR2-Artemin Immune-Inflammation Axis in Acute Myeloid Leukemia.Mediators of inflammation · 2026Article
- Targeting sex-specific DRG inflammation and neurofibrosis to prevent Bortezomib-induced neuropathy.Brain, behavior, and immunity · 2025Article
- Review
- Deciphering the bone marrow microenvironment's role in multiple myeloma immunotherapy resistance.Frontiers in immunology · 2025Review
- Bone marrow inflammation in haematological malignancies.Nature reviews. Immunology · 2024Review
- Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells.Heliyon · 2024Review
- Role of Immune Cells and Immunotherapy in Multiple Myeloma.Life (Basel, Switzerland) · 2024Review
- Large-scale bioreactor production of extracellular vesicles from mesenchymal stromal cells for treatment of acute radiation syndrome.Stem cell research & therapy · 2024Article
- Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.Oncotarget · 2024Article
- Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.Frontiers in oncology · 2024Review
- Mesenchymal stem cells-macrophages crosstalk and myeloid malignancy.Frontiers in immunology · 2024Review
- Different evasion strategies in multiple myeloma.Frontiers in immunology · 2024Review
- Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.Biomolecules · 2023Review
- Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.Nature communications · 2023Article
- Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications.Current oncology (Toronto, Ont.) · 2023Review
- Macrophages and Urokinase Plasminogen Activator Receptor System in Multiple Myeloma: Case Series and Literature Review.International journal of molecular sciences · 2023Review
- Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.Blood advances · 2023Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multiple myeloma (MM) is characterized by almost exclusive tropism of malignant cells for the bone marrow (BM) milieu. The survival and proliferation of malignant plasma cells have been shown to rely on interactions with nonmalignant stromal cells, in particular mesenchymal stromal cells (MSCs), in the BM microenvironment. However, the BM microenvironment is composed of a diverse array of cell types. This study examined the role of macrophages, an abundant component of BM stroma, as a potential niche component that supports malignant plasma cells. We investigated the proliferation of MM tumour cell lines when cultured alone or together with MSCs, macrophages, or a combination of MSCs and macrophages, using the carboxyfluorescein succinimidyl ester assay. Consistently, we observed increased proliferation of MM cell lines in the presence of either MSCs or macrophages compared to cell line-only control. Furthermore, the combined co-culture of MSCs plus macrophages induced the greatest degree of proliferation of myeloma cells. In addition to increased proliferation, MSCs and macrophages decreased the rate of apoptosis of myeloma cells. Our in vitro studies provide evidence that highlights the role of macrophages as a key component of the BM microenvironment facilitating the growth of malignant plasma cells in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.